Reference Ranges, Diagnostic and Prognostic Utility of Native <scp>T1</scp> Mapping and Extracellular Volume for Cardiac Amyloidosis: A Meta‐Analysis

  • Tom Kai Ming Wang
    Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio 44195 USA
  • Maria Vega Brizneda
    Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio 44195 USA
  • Deborah H. Kwon
    Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio 44195 USA
  • Zoran B. Popovic
    Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio 44195 USA
  • Scott D. Flamm
    Cardiovascular Imaging Laboratory, Imaging Institute, and Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio 44195 USA
  • Mazen Hanna
    Section of Heart Failure and Cardiac Transplantation, Sydell and Arnold Miller Family Heart and Vascular Institute Cleveland Clinic Cleveland Ohio 44195 USA
  • Brian P. Griffin
    Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio 44195 USA
  • Bo Xu
    Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio 44195 USA

Description

<jats:sec><jats:title>Background</jats:title><jats:p>Cardiac MRI is central to the evaluation of cardiac amyloidosis (CA). Native T<jats:sub>1</jats:sub> mapping and extracellular volume (ECV) are novel MR techniques with evolving utility in cardiovascular diseases, including CA.</jats:p></jats:sec><jats:sec><jats:title>Purpose</jats:title><jats:p>To perform a meta‐analysis of the diagnostic and prognostic data of native T<jats:sub>1</jats:sub> mapping and ECV techniques for assessing CA.</jats:p></jats:sec><jats:sec><jats:title>Study Type</jats:title><jats:p>Systematic review and meta‐analysis.</jats:p></jats:sec><jats:sec><jats:title>Population</jats:title><jats:p>In all, 3520 patients including 1539 with CA from 22 studies retrieved following systematic search of Pubmed, Cochrane, and Embase.</jats:p></jats:sec><jats:sec><jats:title>Field Strength/Sequence</jats:title><jats:p>1.5T or 3.0T/modified Look–Locker inversion recovery (MOLLI) or shortened MOLLI (shMOLLI) sequences.</jats:p></jats:sec><jats:sec><jats:title>Assessment</jats:title><jats:p>Meta‐analysis was performed for all CA and for light‐chain (AL) and transthyretin (ATTR) subtypes. Thresholds were calculated to classify native T<jats:sub>1</jats:sub> and ECV values as not suggestive, indeterminate, or suggestive of CA.</jats:p></jats:sec><jats:sec><jats:title>Statistical Analysis</jats:title><jats:p>Area under the receiver‐operating characteristic curves (AUCs) and hazards ratios (HRs) with 95% confidence intervals (95% CI) were pooled using random‐effects models and Open‐Meta(Analyst) software.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Six studies were diagnostic, 16 studies reported T<jats:sub>1</jats:sub> and ECV values to determine reference range, and six were prognostic. Pooled AUCs (95% CI) for diagnosing CA were 0.92 (0.89–0.96) for native T<jats:sub>1</jats:sub> mapping and 0.96 (0.93–1.00) for ECV, with similarly high detection rates for AL‐ and ATTR‐CA. Based on the pooled values of native T<jats:sub>1</jats:sub> and ECV in CA and control subjects, the thresholds that suggested the absence, indeterminate, or presence of CA were identified as <994 msec, 994–1073 msec, and >1073 msec, respectively, for native T<jats:sub>1</jats:sub> at 1.5T. Pooled HRs (95% CI) for predicting all‐cause mortality were 1.15 (1.08–1.22) for native T<jats:sub>1</jats:sub> mapping as a continuous parameter, 1.19 (1.01–1.40) for ECV as a continuous parameter, and 4.93 (2.64–9.20) for ECV as a binary threshold.</jats:p></jats:sec><jats:sec><jats:title>Data Conclusion</jats:title><jats:p>Native T<jats:sub>1</jats:sub> mapping and ECV had high diagnostic performance and predicted all‐cause mortality in CA.</jats:p></jats:sec><jats:sec><jats:title>Level of Evidence</jats:title><jats:p>1</jats:p></jats:sec><jats:sec><jats:title>Technical Efficacy Stage</jats:title><jats:p>2</jats:p></jats:sec>

Journal

Citations (2)*help

See more

Report a problem

Back to top